Evaluation of plasma neurofilament light chain and glial fibrillary acidic protein in myasthenia gravis: A controlled cohort study
Arta Grosmane-Bataraga, Evita Saluvēra, Marija Roddate, Vladimirs Krutovs, Kaj Blennow, Henrik Zetterberg, Maksims Zolovs, Nataļja Kurjāne · 2026
Read Evaluation of plasma neurofilament light chain and glial fibrillary acidic protein in myasthenia gravis: A controlled cohort study by Arta Grosmane-Bataraga, Evita Saluvēra, Marija Roddate, Vladimirs Krutovs, Kaj Blennow, Henrik Zetterberg, Maksims Zolovs, Nataļja Kurjāne (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0352017.txt.
Description
Arta Grosmane-Bataraga and seven colleagues report this 2026 PLOS One study testing whether two blood proteins can serve as markers for myasthenia gravis, a disease in which the immune system weakens muscles. The proteins are useful in several brain and nerve diseases, so the team measured them in ninety patients and forty healthy volunteers, and compared levels with standard severity scores.
Neither protein differed between patients and controls, and neither tracked with disease severity, past crises, or treatments. The authors conclude plainly that these markers should not be adopted for monitoring this disease, despite their value elsewhere. As one of the larger controlled analyses of its kind, the study helps steer the search for myasthenia-specific blood markers in other directions.
Catalog record
| CREATOR | Arta Grosmane-Bataraga, Evita Saluvēra, Marija Roddate, Vladimirs Krutovs, Kaj Blennow, Henrik Zetterberg, Maksims Zolovs, Nataļja Kurjāne |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20462 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |